Explore specialist reconstruction and emerging cell-therapy research, starting with a clear understanding of the evidence.
Discuss your options →
These pages provide assessment and research information. They do not confirm that a named technology is offered by REGENIM or its partners. Before any referral or treatment, the team must confirm the provider, local authorisation, indication and availability.
MACI uses a patient’s cultured cartilage cells on a membrane for selected knee cartilage defects. It involves surgery and rehabilitation, rather than a general stem-cell injection.
MACI prescribing information ↗RECELL prepares an autologous skin-cell suspension for specific wound indications. A trained reconstructive specialist determines the appropriate technique and whether it is relevant to the wound.
FDA RECELL information ↗Histotripsy uses focused ultrasound to mechanically destroy targeted liver tissue, including tumours. An oncology and hepatobiliary team must assess suitability and the overall cancer-care plan. This is not an infusion or a general cancer cure.
FDA device record ↗SYMVESS is an acellular tissue-engineered vascular conduit with a specific US indication for urgent limb-threatening extremity arterial injury when an autologous vein graft is not feasible. It is not an elective longevity treatment.
FDA SYMVESS information ↗Bemdaneprocel is being studied for Parkinson’s disease. A discussion can examine the published evidence and trial eligibility; it does not establish that treatment or trial enrolment is available through REGENIM.
ClinicalTrials.gov study record ↗Stem-cell-derived islet therapies, including zimislecel, are being investigated for selected people with type 1 diabetes. These approaches can involve immunosuppression and substantial risks. Continue established diabetes care; this page does not offer a routine cure.
ClinicalTrials.gov study record ↗Fisetin and other senolytic approaches remain subjects of clinical investigation. Research does not establish that a commercial protocol reverses ageing or extends human life.
ClinicalTrials.gov study record ↗A specialist should explain established alternatives, expected benefit, uncertainty, risks, follow-up and cost. Trial eligibility is assessed by the study team; a consultation does not guarantee enrolment.
Arrange a consultation →